







an Open Access Journal by MDPI

# **Development of Innovative Formulations for Breast Cancer Chemotherapy**

Guest Editors:

#### Prof. Dr. Ana Isabel Torres-Suárez

Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain

#### Dr. Ana Isabel Fraguas-Sánchez

Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain

Deadline for manuscript submissions:

closed (28 February 2022)

# **Message from the Guest Editors**

Breast cancer is a major health problem in women worldwide, being one of the most diagnosed cancers and one of the leading causes of cancer death. Chemotherapy represents one of main treatment options, especially in advanced stages of the disease or in certain breast cancer subtypes, such as triple negative breast cancer. However, the high toxicity, low aqueous solubility and rapid in vivo clearance of most antineoplastics limit their clinical use. To resolve these challenges, new innovative formulations, most of them based on micro and nanomedicine, are being investigated.













an Open Access Journal by MDPI

## **Editor-in-Chief**

#### Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

## **Message from the Editor-in-Chief**

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

#### **Contact Us**